AB Science has announced the publication of results from the first randomized Phase III study of Masican (masitinib) in treatment...
Bristol Myers Squibb announced that the FDA approved Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer
AB Science SA announced that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide. This decision follows consultation with the French regulatory authorities (ANSM)and other regulatory agencies.
Results of the MPACT Phase III clinical trial of Abraxane (paclitaxel protein-bound particles for injectable suspension), from Celgene, in combination...
AB Science has announced results from phase III study of Masican (masitinib), in the treatment of adult patient with severe...
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.
Background: The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We aimed to determine the efficacy of this combination in patients with ovarian cancer.
Halozyme Therapeutics announced that the HALO-301 Phase III clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for...
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia).
Boston Biomedical/Sumitomo Dainippon announced that the Phase III CanStem111P study evaluating the safety and efficacy of investigational agent napabucasin plus...